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The risk of long-term mortality and its predictors following convulsive status epilepticus in childhood are uncertain. We report
mortality within 8 years after an episode of convulsive status epilepticus, and investigate its predictors from a paediatric,
prospective, population-based study from north London, UK. In the current study, we followed-up a cohort previously ascer-
tained during a surveillance study of convulsive status epilepticus in childhood. After determining the survival status of the
cohort members, we defined cause of death as that listed on their death certificates. We estimated a standardized mortality ratio
to compare mortality in our cohort with that expected in the reference population. Multivariable Cox regression analysis was
used to investigate any association between the clinical and demographic factors at the time of status epilepticus and subse-
quent risk of death. The overall case fatality was 11% (95% confidence interval 7.5–16.2%); seven children died within 30 days
of their episode of convulsive status epilepticus and 16 during follow-up. The overall mortality in our cohort was 46 times
greater than expected in the reference population, and was predominantly due to higher mortality in children who had
pre-existing clinically significant neurological impairments when they had their acute episode of convulsive status epilepticus.
Children without prior neurological impairment who survived their acute episode of convulsive status epilepticus were not at a
significantly increased risk of death during follow-up. There were no deaths in children following prolonged febrile convulsions
and idiopathic convulsive status epilepticus. A quarter of deaths during follow-up were associated with intractable seizures/
convulsive status epilepticus, and the rest died as a complication of their underlying medical condition. On regression analysis,
presence of clinically significant neurological impairments prior to convulsive status epilepticus was the only independent risk
factor for mortality. In conclusion, there is a high risk of death within 8 years following childhood convulsive status epilepticus
but most deaths are not seizure related. Presence of pre-existing clinically significant neurological impairments at the time of
convulsive status epilepticus is the main risk factor for mortality within 8 years after the acute episode. The attributable role of
convulsive status epilepticus on mortality remains uncertain, but appears less than is generally perceived.
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Introduction
Convulsive status epilepticus (CSE) is the most common medical
neurological emergency in childhood, and is associated with sig-
nificant short-term morbidity and mortality (Chin et al., 2004;
Raspall-Chaure et al., 2006). However, the risk of and predictors
of long-term mortality remain uncertain. Reduction of mortality
requires identification of such predictors so that strategies that
minimize the risk of death can be developed. Mortality within
30 days of an episode of CSE due to all causes has previously
been reported to be between 2.7% and 5.2%, but there are no
data on mortality following childhood CSE beyond this period
(Raspall-Chaure et al., 2006). Previous studies on childhood-onset
epilepsy have reported that status epilepticus does not significantly
increase the risk of death during follow-up, but these studies did
not include children with CSE who did not have a diagnosis of
epilepsy (e.g. prolonged febrile convulsions and acute symptom-
atic CSE) (Sillanpaa and Shinnar, 2002; Stroink et al., 2007).
Much of what is known about the outcomes following CSE in
childhood is from hospital-based studies or from population-based
studies that include both adults and children, which may not re-
flect the true picture of CSE in the general childhood population
(Logroscino et al., 2002; Raspall-Chaure et al., 2006). Existing
literature suggests that there is an association between short-term
mortality following CSE and clinical factors at the time of the
episode, including aetiology, age, duration and character (intermit-
tent or continuous CSE) (Raspall-Chaure et al., 2006; Sadarangani
et al., 2008). Whether any of these clinical factors or demographic
features has any association with longer term mortality is yet to be
determined.
Our group carried out the first population-based study restricted
to CSE in childhood, the North London Convulsive Status
Epilepticus Surveillance Study (NLSTEPSS), and found that the in-
cidence, aetiology and short-term mortality are different in chil-
dren compared with adults (Chin et al., 2006). There were 219
survivors beyond their acute hospital admission for CSE and we
have contemporaneous demographic and clinical data that were
obtained during their episode of CSE for all children. In an ongoing
study, the Status Epilepticus Outcomes Study (STEPSOUT), we are
now following up this unique cohort in order to determine the
frequency of adverse outcomes, including mortality, and to iden-
tify factors that predict those outcomes. In this article, we report
on mortality within 8 years after CSE and investigate the factors
associated with mortality.
Patients and methods
STEPSOUT involves follow-up of the 226 children ascertained during
NLSTEPSS. The details of recruitment during NLSTEPSS have been
reported elsewhere (Chin et al., 2006). In summary, over a 2-year
period and using a multi-tiered notification system set up within a
collaborative network of 21 hospitals, north London children with
CSE were identified by their local paediatrician and the linked-
anonymized clinical and demographic data shared with the central
research team.
In the current follow-up study, subjects are being enrolled through
local collaborators within the original collaborative north London net-
work. For each subject, NLSTEPSS identification numbers were used to
recall patient identifiable information. The survival status of each child
was determined by examining their hospital records and confirmed by
checking their survival status on the NHS Care Records Service, to
ensure that all deaths in our cohort are accurately recorded. Care
Records Service is a national electronic record-keeping service that
maintains up-to-date demographic and key health information, includ-
ing survival status, for all users of the NHS (www.nhscarerecords.nhs.
uk). Death certificates of all deceased children were obtained from the
UK General Register Office (www.gro.gov.uk), with date of death and
cause of death defined as stated on the certificates. Clinical back-
ground data on each subject in the study were obtained from the
original NLSTEPSS database.
We took a pragmatic decision to keep the diagnostic categories for
CSE as classified at the time of CSE and not change the categories
according to the information acquired later during the follow-up. This
is because the follow-up clinical information is not yet available on all
the subjects, and clinical prognostication would be based on the infor-
mation available at the time of CSE.
Statistical analysis
The mortality rate in our cohort was compared with that expected in
the population of north London matched for age to estimate a stan-
dardized mortality ratio (SMR). Case fatality was determined as the
number of deaths within the cohort during the follow-up period
divided by the total number of children in the cohort. The number
of person-years of follow-up was calculated for all participants in the
cohort. Mortality rate was estimated as the death rate per 1000
person-years of follow-up for study subjects. The data for calculating
mortality in the reference population (population estimates from 2002
to 2009) were obtained from the UK Office for National Statistics
(www.ons.gov.uk). SMR was calculated as the observed number of
deaths in the study cohort divided by the expected number of deaths
during the same time period in the age-matched population of north
London. The 95% confidence interval (CI) of the SMR was calculated
using a standard Poisson-based method.
All statistical analyses were performed on SPSS version 19.0, and
StatXact version 4.0 using a complete case analysis approach. After
initial descriptive analysis, we used Cox regression analysis to estimate
survival following CSE and to investigate the predictors of mortality.
We used difference in proportions and Mann–Whitney U test for
comparing the follow-up cohort with those lost to follow-up.
To investigate the clinical and demographic factors associated with
increased mortality, the subjects were grouped on the basis of pres-
ence or absence of clinically significant neurological impairment (motor
and/or cognitive) prior to CSE. Children with pre-existing clinically
significant neurological impairments, with or without epilepsy, at the
time of CSE (i.e. those with remote symptomatic or cryptogenic CSE)
were incorporated into Group 1. Those who had no prior neurological
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impairments or had epilepsy without additional neurological impair-
ments (i.e. those with prolonged febrile convulsions or acute symp-
tomatic or idiopathic or unclassified CSE) were incorporated into
Group 2.
We used Cox regression analyses to identify any factors significantly
associated with death as the outcome and clinical and demographic
factors as risk factors. Factors significantly associated with the outcome
on univariable analysis were then entered in the multivariable models
to test their independent association. Any factors not reaching a sig-
nificance level of 10% (P4 0.1) on univariable analysis were subse-
quently included in the final multivariable model to identify any factors
that were associated with the outcome only after adjustment for other
factors. The demographic factors examined were age at CSE, gender,
ethnicity and Index of Multiple Deprivation (2004) scores as indicator
of socio-economic status (Chin et al., 2009). The higher the Index of
Multiple Deprivation score, the more socio-economically deprived are
the subjects. The clinical factors investigated were first-ever CSE (inci-
dent) versus a past history of CSE, duration of CSE (30–60 min versus
460 min), intermittent versus continuous CSE, type of CSE (focal
versus generalized onset) and presence or absence of clinically signifi-
cant neurological impairment prior to CSE (Group 1 versus Group 2).
Ethics
The study is approved by the UCL Institute of Child Health/Great
Ormond Street Hospital Research Ethics Committee.
Results
Of the 226 children ascertained during NLSTEPSS, 20 were lost-
to-follow-up, and therefore information on the survival status was
available for 206 (91%, 95% CI 87–94%). The clinical and demo-
graphic characteristics of the 20 children lost to follow-up were
similar to those in which survival data were available with the
exception that those lost to follow-up were less socio-economic-
ally deprived (median Index of Multiple Deprivation 2004 score of
35.66 in follow-up and 28.72 in lost to follow-up) (Table 1).
In the 206 children on whom survival information was available,
52% were male and 57% had no clinically significant neurological
impairment prior to CSE. In most, the episode of CSE at inclusion
in NLSTEPSS was their first ever (incident) CSE (78%), was
460 min in duration (61%) and was of generalized seizure type
(63%) (Table 1). The median duration of follow-up was 93.66
months (range 0.03–104.3).
Twenty-three children (12 male) died within 8 years of their
episode of CSE (case fatality = 11%, 95% CI 7.5–16.2%; mortality
rate = 15.37/1000 person-years, 95% CI 10.3–23.0). Seven chil-
dren died during the hospital stay for their episode of CSE (within
30 days) (short-term case fatality = 3%, 95% CI 1.5–6.2), and the
remaining 16 during follow-up. For the 30-day survivors, the over-
all median time to death following an episode of CSE was 52.8
months (range 1.0–88.8). Three of the seven children who died
during the acute period had acute symptomatic CSE (acute bac-
terial meningitis) and the remaining four had remote symptomatic
CSE (progressive neurological disorders). The diagnostic category
of CSE in those who died during the follow-up were remote symp-
tomatic (n = 12), cryptogenic (n = 3) and acute symptomatic
(n = 1). There were no deaths in the children who had prolonged
febrile convulsions or idiopathic CSE.
The SMR was 46.1 (95% CI 28.6–70.5) for the whole cohort
compared with the reference population of north London, and
was 30.8 (95% CI 16.8–51.6) for 30-day survivors (Table 2). In
children with pre-existing clinically significant neurological impair-
ments (Group 1), the SMR was 91.4 (95% CI 53.2–146.3), and in
those with no pre-existing impairments (Group 2), it was 14.8
(95% CI 4.0–37.9). The mortality in 30-day survivors with no
pre-existing impairments was not significantly different from the
reference population (SMR 3.7, 95% CI 0.1–20.6).
On Cox regression, factors that significantly predicted mortality
on univariable analysis were presence of clinically significant
neurological impairment prior to CSE [hazard ratio (HR) 6.7
95% CI 2.3–19.7, P = 0.001] and previous history of CSE at the
time of presentation (HR 2.7, 95% CI 1.18–6.2, P = 0.018). On
multivariable analysis, the only statistically significant predictor of
subsequent mortality was the presence of clinically significant
neurological impairment prior to CSE (Table 3).
Among the 30-day survivors, deaths were observed from
1 month after the episode of CSE in those with pre-existing neuro-
logical impairments, and occurred at regular intervals throughout
the follow-up. In contrast, the only death in the child with acute
symptomatic CSE occurred 5 years following the episode of CSE
(Fig. 1). The survival estimates for individual diagnostic categories
of CSE show that the life expectancy is most severely affected in
children with an underlying progressive neurological disorder with
80% of them not surviving for 20 months after the episode of
CSE (Fig. 2). This is followed by cryptogenic CSE and remote
symptomatic CSE. Most deaths in acute symptomatic CSE
occurred within 30 days of an episode of CSE.
The causes of death as stated on their death certificates and the
diagnostic category of CSE are listed in Table 4. A post-mortem
examination was performed on three children (13%). All three
deaths within 30 days in children with acute symptomatic CSE
were due to complications of the underlying cause (acute bacterial
meningitis). Only one child who had acute symptomatic CSE died
during follow-up (5 years after the index episode of CSE), and the
certified primary cause of death was status epilepticus. Among
those with remote symptomatic CSE, the primary certified cause
of death was respiratory complications (n = 5), small bowel com-
plications (n = 2), intractable seizures/status epilepticus (n = 2),
acute complications of underlying medical condition (n = 2) and
the underlying medical condition/diagnosis (n = 5). In those who
had cryptogenic CSE, one each was certified to have died due to
status epilepticus, severe sepsis and sudden cardiac death with
myocarditis.
Discussion
This is the first paediatric population-based study reporting mor-
tality beyond 30 days following an episode of CSE. The main
findings of our study are that: (i) children with CSE are 46 times
more likely to die within 8 years after their CSE compared with the
rest of the unaffected population; (ii) a history of pre-existing
neurological impairment, with or without accompanying epilepsy,
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at the time of CSE (remote or cryptogenic CSE) is a major risk
factor for death with no evidence that other clinical or demo-
graphic factors increase risk of death; (iii) there were no deaths
following prolonged febrile convulsions and idiopathic CSE; (iv)
cardio-respiratory complications and/or intractable seizures are
the most commonly reported causes of death; and (v) the attrib-
utable role of CSE itself on mortality, rather than the underlying
cause of CSE, could be less than generally perceived.
Table 1 Clinical and demographic characteristics at the time of CSE of the follow-up cohort and those lost to follow-up
Characteristic Followed-up (%),
n = 206
Lost to follow-up (%),
n = 20
Difference in proportion,
(95% CI)
Gender
Male 107 (52) 10 (50) 0.02 (0.19 to 0.23)
Female 99 (48) 10 (50)
Median age at CSE, months (range) 32.3 (1–192) 52 (6–177) 0.076*
Clinically significant neurological impairment prior to CSE
Present (Group 1) 89 (43) 8 (40) 0.03 (0.19 to 0.22)
Absent (Group 2) 117 (57) 12 (60)
Diagnostic category of CSE
Prolonged febrile convulsions 45 (22) 5 (25) 0.03 (0.25 to 0.12)
Acute symptomatic 35 (17) 1 (5) 0.12 (0.07 to 0.19)
Idiopathic 23 (11) 5 (25) 0.14 (0.36 to 0.01)
Cryptogenic 9 (4.5) 0 (0) 0.04 (0.2 to 0.08)
Remote static 72 (35) 7 (35) 0.0 (0.22 to 0.18)
Remote progressive 8 (4) 1 (5) 0.01 (0.2 to 0.04)
Unclassified 14 (6.5) 1 (5) 0.02 (0.17 to 0.07)
CSE occurrence
First-ever (Incident) 160 (78) 15 (75) 0.03 (0.12 to 0.25)
History of CSE (Recurrence) 46 (22) 5 (25)
Seizure duration
30–60 min 81 (39) 12 (60) 0.2 (0.4 to 0.02)
460 min 125 (61) 8 (40)
Seizure character
Continuous 102 (49.5) 9 (45) 0.05 (0.17 to 0.25)
Intermittent 104 (50.5) 11 (55)
Seizure type
Focal 17 (8) 1 (5) 0.03 (0.15 to 0.09)
Secondarily generalized 59 (29) 6 (30) 0.01 (0.24 to 0.15)
Primary generalized 130 (63) 13 (65) 0.02 (0.20 to 0.20)
Ethnicity
White 76 (37) 9 (45) 0.08 (0.30 to 0.12)
Black 36 (17) 6 (30) 0.119 (0.35 to 0.04)
Asian 64 (31) 5 (25) 0.06 (0.16 to 0.21)
Mixed 13 (6) 0 (0) 0.06 (0.10 to 0.10)
Other 17 (8) 0 (0) 0.08 (0.08 to 0.13)
Socio-economic status
Median Index of Multiple Deprivation 2004 scores 35.66 28.72 0.048*
*P-value on Mann–Whitney U test.
Table 2 Mortality in children following an episode of convulsive status epilepticus
Follow-up
(person-years)
Mortality for the whole cohort Mortality for 30-day survivors
Observeda Expected SMR (95% CI) Observeda Expected SMR (95% CI)
Overall 1495.8 21 0.455 46.1 (28.6–70.5) 14 0.455 30.8 (16.8–51.6)
Children with neurological
impairment prior to CSE
610.9 17 0.186 91.4 (53.2–146.3) 13 0.186 69.9 (37.2–119.5)
Children without neurological
impairment prior to CSE
884.9 4 0.27 14.8 (4.0–37.9) 1 0.27 3.7 (0.1–20.6)
a Two deaths that occurred in 2010 were not included in SMR calculation as the vital statistics for the reference population for the year 2010–11 are not yet available.
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Although the overall mortality in our cohort was 46 times higher
than expected in the reference population, this effect was pre-
dominantly seen in children with pre-existing clinically significant
neurological impairments at the time of CSE (remote symptomatic
and cryptogenic CSE). Almost all deaths in children with acute
symptomatic CSE occurred within 30 days of their episode of
CSE, and those who survive beyond this period were not at a
significantly increased risk of death compared with the reference
population.
The overall risk of death following CSE was almost seven times
higher in children with pre-existing neurological impairments
(motor and/or cognitive) compared with those who were previ-
ously neurologically normal; and this risk increased to 19 times in
those who survived beyond 30 days of their episode of CSE. All
deaths in previously neurologically normal children occurred in
those with acute symptomatic CSE; three children with acute bac-
terial meningitis died during the acute episode and one with viral
encephalitis died 5 years later. There were no deaths in children
following prolonged febrile convulsions, an observation similar to
the previous reports of very low risk of mortality following pro-
longed febrile convulsions, and similar to the mortality in simple
febrile seizures (Verity et al., 1993; Logroscino et al., 2002;
Vestergaard et al., 2008).
We found that none of the clinical and demographic factors at
the time of CSE were independent predictors of subsequent mor-
tality except pre-existing neurological impairment. Previous studies
Figure 1 Cumulative risk of death following an episode of CSE according to presence of pre-existing neurological impairment at the time
of CSE (survival curves according to presence or absence of previous CSE are superimposed for comparison).
Table 3 Regression analysis for predictors of death within 8 years following an episode of CSE
Variable Univariable analysis Multivariable analysis
Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value
Pre-existing clinically significant neurological impairment at the time of CSE 6.7 (2.3–19.7) 0.001 6.7 (2.3–19.7) 0.001
Gender (male versus female) 0.99 (0.43–2.24) 0.98 – –
Ethnicity (white, black, Asian, other) 1.05 (0.43–2.6) 0.51 – –
Socio-economic status (IMD, 2004) 1.0 (0.98–1.04) 0.618 – –
Age at CSE (months) 1.02 (0.92–1.14) 0.689 – –
Previous CSE at presentation (recurrence versus incident) 2.7 (1.18–6.2) 0.018 1.8 (0.77–4.3) 0.173
Duration of CSE (30–60 min versus 460 min) 1.91 (0.75–4.8) 0.173 – –
Character of CSE (continuous versus intermittent) 1.08 (0.47–2.44) 0.858 – –
Type of CSE (focal versus generalized onset) 1.36 (0.56–3.3) 0.499 – –
IMD = Index of Multiple Deprivation.
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have reported higher mortality in individuals with prolonged status
epilepticus (460 min), continuous status epilepticus (compared
with intermittent) and higher age, but this observation was valid
only in adults and not for the paediatric population (Towne et al.,
1994; DeLorenzo et al., 1999; Waterhouse et al., 1999). Also,
none of the previously reported predictors of short-term mortality
following CSE in children, such as acute symptomatic cause of
CSE, young age at onset, longer duration of CSE and focal-onset
of CSE, were independently associated with mortality beyond 30
days in our cohort (Raspall-Chaure et al., 2006; Sadarangani
et al., 2008). The observed differences in our study and other
reported hospital-based studies may at least in part be related to
the inclusion of more severe cases in hospital-based studies. The
frequency of CSE and medication non-compliance may also po-
tentially increase overall mortality. STEPSOUT is an ongoing study
and the surviving cohort members are currently being recruited to
determine the neurological, neuroimaging, cognitive and behav-
ioural outcomes. The details on medication compliance, epilepsy
control and frequency of CSE during follow-up are not available
on all cohort members and we were not therefore able to adjust
for these factors in our modelling.
We report the cause(s) of death in our cohort as stated on their
death certificates. Most deaths within 30 days of an episode of
CSE were as a consequence of complications of the underlying
cause, such as acute bacterial meningitis or a progressive neuro-
logical disorder. Even among the 30-day survivors, the majority of
deaths seem to have been associated with complications of their
underlying brain disorder, rather than as a direct consequence of
CSE. Only four deaths were seizure related; three as a result of
CSE and one as a result of intractable seizures. There were no
sudden unexpected deaths in epilepsy (SUDEP) or accidental
deaths. This is in contrast to the observation by Aicardi and
Chevrie (1970), who reported that about half the deaths in their
cohort with CSE were seizure related. There are several possible
explanations for this observed difference. The first was that the
Aicardi study (1970) was hospital based, and CSE was defined as
continued seizure activity lasting at least 60 min rather than the
30 min used in our study. Thus, the children in the Aicardi (1970)
study may reflect children with more severe conditions compared
with our cohort. It is also possible that improvements in acute
management of CSE in children in recent years may explain
reduced risk of death as a direct consequence of CSE. Another
explanation may be inaccuracies in the cause of death as stated
on the death certificates as only 3 out of 23 in our study had
autopsies, and the stated cause of death on certificates may not
reflect circumstances surrounding death (Sillanpaa and Shinnar,
2010). It is possible that the actual cause of death may be due
to seizure activity although not listed as such, e.g. unobserved
seizure activity may lead to aspiration and subsequent respiratory
failure.
As the main predictor of mortality is presence of pre-existing
clinically significant neurological impairment at the time of CSE, it
becomes important to ask whether CSE itself has any additional
impact on subsequent mortality. There are no reported paediatric
studies designed to address the independent influence of CSE on
long-term mortality. Ideally, a direct comparison of the mortality in
children with a pre-existing significant neurological disorder and
no CSE, with a similar population of children with CSE, or mortal-
ity between idiopathic epilepsy without CSE and with CSE may
help to determine the additional impact of CSE on mortality.
However, even such an approach may not provide a satisfactory
answer to this important question as the outcome may still be
Figure 2 Cumulative risk of death following an episode of CSE according to the diagnostic category of CSE, showing that the life
expectancy is most severely affected in children with an underlying progressive neurological disorder and no deaths in prolonged
febrile convulsions, idiopathic and unclassified CSE.
2824 | Brain 2011: 134; 2819–2827 S. S. Pujar et al.
confounded by the severity of the underlying structural/functional
brain disorder and CSE itself could be a marker of the severity.
An indirect way of analysing the attributive role of CSE on mor-
tality could be by comparing the mortality in idiopathic CSE in our
cohort with the reported mortality in children with idiopathic epi-
lepsy, and mortality in children with neurological impairments in
our cohort with that of remote symptomatic epilepsy and cerebral
palsy as these are the main groups that make up the subcategory
Table 4 Clinical characteristics and cause of death in the deceased
Case Age at
CSE (years)
Age at
death (years)
Diagnostic category of CSE Cause of death (as stated on death certificate)
1a 1.2 1.2 Acute symptomatic I (a) Brainstem herniation
(b) Cerebral oedema
(c) Pneumococcal meningitis
2a 2.1 2.1 Acute symptomatic I (a) Increased intracranial pressure, coning
(b) Meningococcal meningitis
3a 1.0 1.0 Acute symptomatic I (a) Respiratory arrest
(b) Pneumococcal meningitis
II Cerebral palsy, ventriculo-peritoneal shunt for hydrocephalus,
intraventricular haemorrhage at birth
4a 5.6 5.6 Remote symptomatic I (a) Bronchopneumonia
(b) Intractable epilepsy
(c) West syndrome
II Global developmental delay
5a 5.1 5.1 Remote symptomatic I (a) Acute encephalopathy
(b) Glutaric aciduria type I
6a 0.4 0.4 Remote symptomatic I (a) Brain infarction
(b) Congenital lactic acidosis
7a 0.5 0.5 Remote symptomatic I (a) Progressive neurodegenerative disorder
(b) Congenital mitochondrial disorder
8b 3.7 8.4 Acute symptomatic I (a) Acute brain swelling/haemorrhagic infarction
(b) Status epilepticus
II Influenza A infection
9b 3.0 9.2 Cryptogenic I (a) Sudden cardiac death
(b) Acute lymphocytic myocarditis
II Epilepsy
10 9.5 17.0 Cryptogenic I (a) Septic shock with multiple organ failure
(b) Community acquired pneumonia
II Epilepsy
11 3.2 9.6 Cryptogenic I (a) Acute cardiorespiratory failure
(b) Status epilepticus
(c) Dravet syndrome
12 5.2 8.5 Remote symptomatic I (a) Lower respiratory tract infection
(b) Intractable seizure disorder
II Gastro oesophageal reflux
13 12.2 16.3 Remote symptomatic I (a) Pneumonia
(b) Cerebral palsy, spastic quadriplegia, epilepsy
II Gastro oesophageal reflux with gastrostomy
14b 7.8 13.1 Remote symptomatic I (a) Small bowel infarction
(b) Volvulus
II Cerebral palsy
15 1.5 7.0 Remote symptomatic I (a) Cytochrome C oxidase deficiency
16 2.7 4.2 Remote symptomatic I (a) Neurodegenerative disorder of unknown aetiology
17 13.4 13.5 Remote symptomatic I (a) Status epilepticus
(b) Degenerative brain disease
(c) Mitochondrial encephalopathy
18 0.6 1.2 Remote symptomatic I (a) Respiratory failure
II Neurodegenerative disorder
19 0.7 1.1 Remote symptomatic I (a) Congenital denervating neurological condition
20 11.2 16.8 Remote symptomatic I (a) Bronchopneumonia
II Cerebral palsy
21 2.6 3.0 Remote symptomatic I (a) Severe pyridoxine deficiency
(b) Severe epilepsy
22 1.0 6.9 Remote symptomatic I (a) Ileus
(b) Severe complex neurological disability
23 2.3 4.2 Remote symptomatic I (a) Intractable seizures
II Global developmental delay
a Deaths within 30 days of CSE.
b Had post-mortem examination.
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of children with pre-existing neurological problem in our cohort.
There were no deaths in children who had idiopathic CSE in our
cohort (SMR 0, 95% CI 0.0–3.68), an observation similar to the
low mortality reported in children with idiopathic epilepsy (Harvey
et al., 1993; Callenbach et al., 2001; Camfield et al., 2002; Berg
et al., 2004; Geerts et al., 2010; Sillanpaa and Shinnar, 2010). The
SMR for children with significant neurological impairment prior to
their episode of CSE in our study was 91.4 (95% CI 53.2–146.3).
In comparison, reported SMRs in children with symptomatic epi-
lepsies range between 22.9 (95% CI 7.9–37.9) and 49.7 (95% CI
31.7–77.9) (Harvey et al., 1993; Callenbach et al., 2001; Berg
et al., 2004; Geerts et al., 2010). The mortality in our cohort
with significant neurological impairment prior to CSE appears to
be higher than that reported for remote symptomatic epilepsy.
However, children classified as having remote symptomatic epi-
lepsy by definition do not necessarily have major neurological im-
pairments and therefore the comparison with our group is not very
robust (Engel, 2001). The mortality in our cohort is comparable
with the reported mortality in children with cerebral palsy, a
cohort likely to have similar neurological impairments (SMR 36.4
for mild and 102.8 for severe cerebral palsy, 95% CI not pro-
vided); however, a significant proportion of children with severe
cerebral palsy probably had epilepsy and some also experienced
episodes of CSE (Strauss et al., 1999). All these comparisons need
to be interpreted with caution, as they do not take into consider-
ation the heterogeneity of the study populations, the severity of
underlying conditions in different cohorts and the unreported pos-
sible confounders affecting the outcome.
Long-term follow-up studies have reported no significant differ-
ence in mortality in children with epilepsy with or without status
epilepticus (Sillanpaa and Shinnar, 2002; Stroink et al., 2007).
Although a history of prior CSE was associated with increased
long-term mortality on univariable analysis in some studies, this
was no longer significant after adjusting for other clinical factors,
and the underlying diagnosis was the major predictor of mortality
(Callenbach et al., 2001; Camfield et al., 2002; Sillanpaa and
Shinnar, 2002, 2010; Berg et al., 2004a, b).
The available data therefore suggest that CSE does not substan-
tially increase the risk of death in neurologically normal children
who survive the acute episode of CSE, and any impact it may have
on increasing long-term mortality is seen primarily in children with
significant underlying brain disorder. This, however, needs con-
firmation from studies designed to investigate the additional
impact of CSE on mortality without being confounded by severity
of underlying brain disorder, and a possible approach could be by
comparing the mortality associated with short seizures against that
with CSE in children without an identifiable underlying aetiology
(e.g. febrile seizures, idiopathic epilepsy). One such study done in
adult population showed a non-significant 2.4-fold increased risk
of death at 10 years in incident idiopathic/cryptogenic CSE com-
pared with short seizures (adjusted relative risk 2.4, 95% CI 0.9–
6.3) (Logroscino et al., 2008). However, the study was limited by
a small sample size, and the increased risk was restricted to the
elderly and those who later developed epilepsy.
Our study is the largest prospective paediatric population-based
cohort of CSE in resource-rich countries. Despite this, it is possible
that lack of statistical significance for some of the clinical and
demographic factors could be due to our modest sample size.
As is inevitable in follow-up studies, there will be some degree
of attrition but our 9% attrition is within the acceptable range
for follow-up cohort studies (Fewtrell et al., 2008). Furthermore,
the children who were lost to follow-up were similar to those for
whom we had follow-up data suggesting that our results are rep-
resentative of the entire CSE cohort. This study, from a
resource-rich country, may well not reflect the longer term mor-
tality in a resource-poor setting where it is already clear that the
mortality within 3 years of an episode of CSE is substantially
higher (Sadarangani et al., 2008).
In summary, our study provides novel information that will be
useful for prognostication. There is a substantially increased risk
for death within 8 years after CSE with having pre-existing clinic-
ally significant neurological disorder at the time of CSE being the
major predictor. The risk of death is not increased in children with
prolonged febrile convulsions and idiopathic CSE, and in those
with acute symptomatic aetiology who survive the acute episode
of CSE. Most deaths during follow-up occur as a complication of
underlying brain disorder rather than seizures themselves. In add-
ition, the study has generated the hypothesis that there is minimal
additional impact of CSE itself on mortality. Case–control studies
specifically designed to investigate this hypothesis are now
required. Although it may be feasible to detect a significant dif-
ference in mortality among those with and without CSE, the chal-
lenge is identifying an appropriate control population. As CSE is
associated with increased morbidity as well as mortality, research
into morbidity following CSE in childhood is needed.
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